W.A.I.T. Indicator


What is the waiting time to access new cancer medications in Latin America?

Smiling Cancer Patient Looking at test results

FIFARMA launches the second version of the W.A.I.T. Indicator Survey measuring the waiting time to access innovative drugs in LATAM


WAIT Indicator: responsible pragmatism in measuring access to new technologies in Latin America


Recent posts

Building Trust and Efficiency: The New Reliance Trial in Pharmaceutical Approvals
3 Cosas Que No Sabia - Victoria Brenes, Directora Ejecutiva de FEDEFARMA
Conozca a Andrea Da Pieve, Head LATAM de Biogen